Omnicell, Inc. (NASDAQ: OMCL) is a company that provides medication management solutions and adherence tools for healthcare systems and pharmacies. It operates in a competitive market with players like McKesson and Cardinal Health. Recently, Piper Sandler set a new price target for Omnicell at $49, a 25.38% increase from its current trading price of $39.08.
The stock experienced a significant drop following a disappointing earnings announcement. It opened at $39.69, down from a previous close of $46.69, and last traded at $38.38. This decline was influenced by Omnicell's earnings per share of $0.40, which missed the consensus estimate of $0.47 by $0.07.
Despite the earnings miss, Omnicell's revenue for the quarter was $313.98 million, slightly above analysts' expectations of $313.36 million. This represents a 2.3% increase compared to the same quarter last year. The company recorded a net margin of 1.69% and a return on equity of 4.10%.
Omnicell has set its guidance for Q1 2026 at $0.26 to $0.36 EPS and for FY 2026 at $1.65 to $1.85 EPS. Management has raised its guidance for FY 2026 and Q1 2026, indicating a positive outlook for the future. The stock has seen a decrease of 16.30% today, dropping by $7.61, with a low of $36.95 and a high of $41.52.
Over the past year, Omnicell's stock has fluctuated between a high of $55 and a low of $22.66. The company's market capitalization is approximately $1.80 billion, with a trading volume of 2,835,483 shares. Despite recent challenges, the new price target suggests potential growth for Omnicell.
